Latest Peplin news

01-Feb-10

LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition read more

Positive Results for LEO Pharma's Phase III Actinic Keratosis Trials on the Face and Scalp read more

Letter to our CDI Holders read more

Archived 2003

31-12-2003			New CFO and Company Secretary
21-11-2003			Acquisition of Portfolio of Potential Therapeutic Products
21-10-2003			2003 AGM Chairman's Address & Executive Slide Presentation
20-10-2003			Share Offer to Existing Peplin Shareholders
10-10-2003			Peplin Confirms New Appointment
06-10-2003			Fund Raising and Other Corporate Developments
22-09-2003			New CEO for Peplin
15-09-2003			Drug Biosynthesis Shows Promise for Peplin
14-09-2003			UK Leukaemia Research Reports High Potency of PEP005 Against AML
08-09-2003			Peplin Delivers 2003 Results
02-06-2003			New Funding Round to Accelerate R&D
10-04-2003			Briefing to ABN AMRO Morgans Healthcare & Biotechnology Forum 10 April 2003
11-03-2003			Progen to Manufacture Anti-Cancer Compound for Peplin
10-02-2003			Three new patents; Half-year revenues up 240%
17-01-2003			Bioshares article on Peplin - Dec 2002